Clinical Trials
192 trialsSafety and Efficacy of Systemic Chemotherapy Plus PD-1 Inhibitor in Combination With Bevacizumab in Gastric Cancer With Peritoneal Metastasis
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients
Zhujiang Hospital
Sequential AG and mFOLFOX Combined With Serplulimab Injection and Bevacizumab Injection in Untreated Advanced Pancreatic Cancer
Zhejiang Cancer Hospital
Sintilimab Combination Therapy Plus IMRT in Nasopharyngeal Carcinoma
Zhejiang Cancer Hospital
A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
Leiden University Medical Center
Dose Escalation and Expansion Clinical Trial of Irinotecan Liposome Combined With Oxaliplatin and 5-FU/LV Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
STRATEGIC-1
GERCOR - Multidisciplinary Oncology Cooperative Group
BELLA
Peter MacCallum Cancer Centre, Australia
Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma
Fudan University
The Efficacy and Safety of Lcaritin Combined With Bevacizumab and FOLFIRI in Treatment of Liver Metastases From Colorectal Cancer
Sir Run Run Shaw Hospital
HCC
CHA University
Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
University Health Network, Toronto
Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC
Hunan Province Tumor Hospital
Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer
Hunan Province Tumor Hospital
Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy
The First Affiliated Hospital of Xinxiang Medical College
FUTURE-SUPER
Fudan University
DEBIRI
Fudan University
Hepatic Arterial Infusion Chemotherapy in Combination With Atezolizumab and Bevacizumab for Second-line Treatment of Patients With Recurrent Liver Cancer After Liver Transplantation
Third Affiliated Hospital, Sun Yat-Sen University
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
REVOLUTION
National Cancer Institute, Naples
RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The First Affiliated Hospital with Nanjing Medical University
INTERACT-II
Catharina Ziekenhuis Eindhoven
POCHI
Federation Francophone de Cancerologie Digestive
SIRTCI
Federation Francophone de Cancerologie Digestive
BEACON
Peter MacCallum Cancer Centre, Australia
Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Sun Yat-sen University
Calizumab Combined With Bevacizumab and Capecitabine in the Treatment of Head and Neck Squamous Cell Carcinoma
Second Affiliated Hospital of Guangzhou Medical University
SELENIUM
Seoul National University Hospital
BRISK
Asan Medical Center
SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial
Sun Yat-sen University
The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab
Fudan University
Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.
Second Affiliated Hospital of Nanchang University
Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC
Samsung Medical Center
Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer
Qingdao Central Hospital
MITO16/MANGO-2
National Cancer Institute, Naples
MITO16MANGO2b
National Cancer Institute, Naples
BEVERLY
National Cancer Institute, Naples
Sintilimab Combined With Bevacizumab and Liver Protective Support Therapy in Unresectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
MiST
University of Leicester
RE-GEND
Kyorin University
Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T
Sun Yat-sen University
Tucidinostat Plus PD-1 Inhibitor and Bevacizumab for Advanced Esophagus Cancer, AEG, Gastric Cancer
Sun Yat-sen University
Clinical Study of Ametinib Combined With Bevacizumab in First-line Treatment of Advanced NSCLC With EGFR-mutations.
The Second Affiliated Hospital of Shandong First Medical University
Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II Study
Sun Yat-sen University